TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
TSHA

Taysha Gene Therapies Inc

Healthcare · Biotechnology · —

5.00$ -2.7% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Taysha Gene Therapies Inc (TSHA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.4% of the shares are freely tradable; institutional investors hold 95.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 95.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 10.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 71.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 14.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 326Mio.

Largest Shareholders

Institutions

Institutions TSHA
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 7.25 23,555,648 +0.0 03/31/2026
The Goldman Sachs Group Inc 6.89 22,369,645 +63.4 03/31/2026
venBio Select Advisor LLC 6.68 21,700,000 +0.0 03/31/2026
BlackRock Inc 5.65 18,365,608 -1.5 03/31/2026
Vestal Point Capital LP 5.54 18,000,000 +30.9 03/31/2026
Morgan Stanley - Brokerage Accounts 5.53 17,965,371 -0.6 03/31/2026
FMR Inc 4.41 14,321,255 +5.9 03/31/2026
RTW INVESTMENTS, LLC 4.21 13,680,248 -16.6 03/31/2026
State Street Corp 3.45 11,209,078 +3.9 03/31/2026
Vanguard Capital Management, LLC 3.15 10,231,502 +0.0 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?